Related Experiment Videos
F-MACHOP in advanced aggressive lymphoma
C Guglielmi1, S Amadori, M Martelli
1Department of Human Biopathology, University La Sapienza Roma, Italy.
Leukemia & Lymphoma
|June 1, 1992
Summary
F-MACHOP chemotherapy is effective for advanced diffuse large cell or small non-cleaved cell lymphoma, with over 60% achieving long-term event-free survival (EFS). Early complete remission (CR) indicates a high cure chance, while F-MACHOP shows potential superiority over MACOP-B.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large cell lymphoma and small non-cleaved cell lymphoma are aggressive non-Hodgkin lymphomas.
- Advanced stages require effective chemotherapy regimens with acceptable toxicity.
Purpose of the Study:
- To evaluate the efficacy and toxicity of the F-MACHOP regimen in adults with advanced diffuse large cell or small non-cleaved cell lymphoma.
- To compare F-MACHOP with MACOP-B in a prospective randomized trial.
Main Methods:
- Ten years of clinical experience with F-MACHOP.
- Prospective comparative randomized trial involving 6 Italian hematologic institutions.
- F-MACHOP regimen designed using cell kinetic and synergistic principles.
Main Results:
- F-MACHOP demonstrated effectiveness with acceptable toxicity in a large proportion of patients.
- Over 60% of patients are expected to achieve long-term event-free survival (EFS).
- Preliminary results suggest F-MACHOP may be superior to MACOP-B, with a trial closed to accrual in September 1991.
Conclusions:
- F-MACHOP is an effective and tolerable regimen for advanced diffuse large cell or small non-cleaved cell lymphoma.
- Achieving complete remission (CR) within 3 courses is a strong predictor of cure.
- F-MACHOP shows promise as a superior treatment option compared to MACOP-B.